Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …

Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine
kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t (9 …

Background Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1
protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from …

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …

When Folkman first suggested a theory about the association between angiogenesis and
tumor growth in 1971, the hypothesis of targeting angiogenesis to treat cancer was formed …

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …